{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T08:47:46Z","timestamp":1786870066358,"version":"build-2736575974"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ctrv.2020.102014","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T20:10:35Z","timestamp":1584994235000},"page":"102014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Thymic epithelial tumors: From biology to treatment"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-0502","authenticated-orcid":false,"given":"Fabio","family":"Conforti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"De Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102014_b0005","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2020.102014_b0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JTO.0000000000000393","article-title":"The impact of thymoma histotype on prognosis in a worldwide database","volume":"10","author":"Weis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0015","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1212\/WNL.42.10.1888","article-title":"The epidemiology of myasthenia gravis in central and western Virginia","volume":"42","author":"Phillips","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ctrv.2020.102014_b0020","series-title":"Major histocompatibility complex (MHC) and peptide binding. bioinformation discovery","first-page":"111","author":"Kangueane","year":"2009"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102014_b0025","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102014_b0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1440-1827.1994.tb02936.x","article-title":"A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma","volume":"44","author":"Koga","year":"1994","journal-title":"Pathol Int"},{"key":"10.1016\/j.ctrv.2020.102014_b0035","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0040","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1097\/JTO.0b013e3181f209a8","article-title":"Thymoma and thymic carcinoma: molecular pathology and targeted therapy","volume":"5","author":"Strobel","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0045","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JTO.0000000000000154","article-title":"ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma refined definitions, histological criteria, and reporting","volume":"9","author":"Marx","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0050","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1097\/JTO.0000000000000297","article-title":"Histologic classification of thymoma: a practical guide for routine cases","volume":"9","author":"Den Bakker","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0055","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/00000478-200212000-00008","article-title":"Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: a retrospective study of 90 tumors","volume":"26","author":"Chalabreysse","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102014_b0060","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/JTO.0000000000000482","article-title":"Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage is superior to histopathologic classifications","volume":"10","author":"Roden","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102014_b0065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaneurol.2016.0603","article-title":"Frequency of Synaptic autoantibody accompaniments and neurological manifestations of thymoma","volume":"73","author":"Zekeridou","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ctrv.2020.102014_b0070","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic Landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2020.102014_b0075","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0003-4975(01)03607-4","article-title":"Primary thymic carcinoma","volume":"73","author":"Liu","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2020.102014_b0080","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-4362.1992.tb02675.x","article-title":"Primary thymic carcinoma and its association with dermatomyositis and pure red cell aplasia","volume":"31","author":"Fong","year":"1992","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102014_b0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2169\/internalmedicine.48.1136","article-title":"Masanori nakagawa polymyositis with atypical pathological features associated with thymic carcinoma","volume":"48","author":"Azuma","year":"2009","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102014_b0090","doi-asserted-by":"crossref","first-page":"e42669","DOI":"10.1371\/journal.pone.0042669","article-title":"Molecular analysis of thymoma","volume":"7","author":"Badve","year":"2012","journal-title":"PlosOne"},{"issue":"22","key":"10.1016\/j.ctrv.2020.102014_b0095","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"305","key":"10.1016\/j.ctrv.2020.102014_b0100","article-title":"Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization","volume":"8","author":"Lee","year":"2007","journal-title":"BMC Genom"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102014_b0105","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2020.102014_b0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/ng.3496","article-title":"High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry","volume":"48","author":"Sun","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2020.102014_b0115","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nn.4276","article-title":"Neurobiology of social behavior abnormalities in autism and Williams syndrome","volume":"19","author":"Barak","year":"2016","journal-title":"Nat Neurosci"},{"issue":"6","key":"10.1016\/j.ctrv.2020.102014_b0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molmed.2017.04.002","article-title":"Pathophysiology of TFII-I: old guard wearing new hats","volume":"23","author":"Roy","year":"2017","journal-title":"Trends Mol Med"},{"issue":"26","key":"10.1016\/j.ctrv.2020.102014_b0125","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1073\/pnas.0803051105","article-title":"Identification of TFII-I family target genes in the vertebrate genome","volume":"105","author":"Chimge","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.ctrv.2020.102014_b0130","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2020.102014_b0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0140","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2020.102014_b0145","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"48","author":"Tesa","year":"2011","journal-title":"Nat Genet"},{"issue":"6009","key":"10.1016\/j.ctrv.2020.102014_b0150","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2020.102014_b0155","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1309\/AJCPG8LFJC0DHDQT","article-title":"Loss of BAP1 expression in basal cell carcinomas in patients with germline BAP1 mutations","volume":"143","author":"Mochel","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"7279","key":"10.1016\/j.ctrv.2020.102014_b0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102014_b0165","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1038\/ncomms4630","article-title":"The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes","volume":"5","author":"Huether","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2020.102014_b0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronne","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102014_b0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2012.288","article-title":"The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics","volume":"27","author":"Abdel-Wahab","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2020.102014_b0180","article-title":"State of the Art of Genetic Alterations in Thymic Epithelial Tumors","volume":"9","author":"Rajan","year":"2014","journal-title":"JTO"},{"key":"10.1016\/j.ctrv.2020.102014_b0185","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1158\/1078-0432.CCR-12-3260","article-title":"Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors","volume":"19","author":"Petrini","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102014_b0190","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3389\/fimmu.2018.02063","article-title":"MicroRNA functions in thymic biology: thymic development and involution","volume":"9","author":"Xu","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2020.102014_b0195","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2014.04.008","article-title":"MicroRNA expression profiling of thymic epithelial tumors","volume":"85","author":"Ganci","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102014_b0200","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/bjc.2015.425","article-title":"A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas","volume":"114","author":"Radovich","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2020.102014_b0205","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12253-016-0144-8","article-title":"Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets","volume":"23","author":"Enkner","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ctrv.2020.102014_b0210","doi-asserted-by":"crossref","first-page":"e0166494","DOI":"10.1371\/journal.pone.0166494","article-title":"Proteomic signatures of thymomas","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS ONE"},{"issue":"20","key":"10.1016\/j.ctrv.2020.102014_b0215","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1158\/0008-5472.CAN-17-1323","article-title":"Therapeutic effects of XPO1 inhibition in thymic epithelial tumors","volume":"77","author":"Conforti","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102014_b0220","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.4049\/jimmunol.181.4.2265","article-title":"Thymic emigration: when and how T cells leave home","volume":"181","author":"Weinreich","year":"2008","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102014_b0225","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.it.2017.07.010","volume":"38","author":"Takaba","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ctrv.2020.102014_b0230","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1097\/JTO.0b013e3181f1f63f","volume":"5","author":"Marx","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102014_b0235","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2249.2004.02384.x","article-title":"Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity","volume":"135","author":"Peterson","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ctrv.2020.102014_b0240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.gene.6363929","article-title":"Autoimmune regulator: from loss to function to autoimmunity","volume":"4","author":"Pitkanen","year":"2003","journal-title":"Genes Immun"},{"key":"10.1016\/j.ctrv.2020.102014_b0245","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1006\/clim.1999.4710","article-title":"Correlation of thymic pathology with HLA in myasthenia gravis","volume":"91","author":"Machens","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ctrv.2020.102014_b0250","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood.V96.12.3872","article-title":"Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease","volume":"96","author":"Hoffacker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102014_b0255","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial\u2014The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0260","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma: A 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102014_b0265","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0270","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0275","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.07.094","article-title":"A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma","author":"Gbolahan","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0285","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1097\/JTO.0b013e3181f21129","article-title":"The role of chemotherapy in advanced thymoma","volume":"5","author":"Schmitt","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0290","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.7079","article-title":"A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma","volume":"24","author":"Loehrer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0295","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2020.102014_b0300","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2020.102014_b0305","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/JTO.0b013e3181e96e30","article-title":"Expression and mutational status of c-kit in thymic epithelial tumors","volume":"5","author":"Petrini","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0310","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0315","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2020.102014_b0320","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to Imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102014_b0325","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102014_b0330","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0335","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0340","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0345","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"issue":"20","key":"10.1016\/j.ctrv.2020.102014_b0350","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"IGF-1R and p-AKT expression in 132 resected thymomas and thymic carcinomas","volume":"116","author":"Zucali","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2020.102014_b0355","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0360","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann Anat"},{"key":"10.1016\/j.ctrv.2020.102014_b0365","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ctrv.2020.102014_b0370","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg Today"},{"key":"10.1016\/j.ctrv.2020.102014_b0375","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2613.2011.00777.x","article-title":"Platelet-derived growth factor and platelet-derived growth factor receptor-alpha expression in the normal human thymus and thymoma","volume":"92","author":"Cimpean","year":"2011","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.ctrv.2020.102014_b0380","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0385","unstructured":"Brett Houk, Carlo Bello, George Demetri et al Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches. In: 9th AACR annual meeting \u2013 Apr 12\u201316, 2008."},{"issue":"suppl_5","key":"10.1016\/j.ctrv.2020.102014_b0390","first-page":"v747","article-title":"Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma; Preliminary results from a multicenter phase II (REMORA) trial","volume":"30","author":"Itoh","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0395","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s13318-017-0403-4","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor","volume":"42","author":"Hussein","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ctrv.2020.102014_b0400","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1177\/0091270004268128","article-title":"Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms","volume":"44","author":"Kim","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102014_b0405","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1016\/j.cllc.2018.06.005","article-title":"RELEVENT Trial: Phase II trial of ramucirumab, carboplatin, and paclitaxel in previously untreated thymic carcinoma\/B3 thymoma with area of carcinoma","volume":"19","author":"Imbimbo","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102014_b0410","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","article-title":"Regulation of mTORC1 by PI3K signaling","volume":"25","author":"Dibble","year":"2015","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.ctrv.2020.102014_b0415","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"PI3K as a potential therapeutic target in thymic epithelial tumors","volume":"11","author":"Alberobello","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0420","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5306\/wjco.v3.i7.111","article-title":"Everolimus plus long acting somatostatin analogs in thymic epithelial malignancies","volume":"2","author":"Palmieri","year":"2012","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0425","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0430","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ejca.2013.11.022","article-title":"Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology","volume":"50","author":"Ravaud","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102014_b0435","doi-asserted-by":"crossref","unstructured":"De Wit D, Schneider TC, Moes DJAR, et al. Everolimus pharmacokinetics and its exposure\u2013toxicity relationship in patients with thyroid cancer. Cancer Chemother Pharmacol 2016;78:63\u201371. Petrini I, Meltzer PS, Zucali PA, et al. Copy number aberrations of BCL2 and CDKN2A\/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis 2012;19;3:e351.","DOI":"10.1038\/cddis.2012.92"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2020.102014_b0440","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8519","article-title":"Efficacy of Milciclib (PHA-848125AC), a pan cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients","volume":"36","author":"Besse","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0445","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0450","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A Phase I\/II trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in thymic epithelial tumors: a clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102014_b0455","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katusya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102014_b0460","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0465","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2020.102014_b0470","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma:a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0475","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"JCO2017773184","author":"Cho","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0480","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single arm multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"EJC"},{"key":"10.1016\/j.ctrv.2020.102014_b0485","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.102014_b0490","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Razak","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102014_b0495","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first line therapy in patients with advanced clear-cell renal-cell carcinoma (Javelin Renal 100): an open label, dose finding and dose expansion, phase I b trial","volume":"19","author":"Choueri","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:23:49Z","timestamp":1759656229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":99,"alternative-id":["S0305737220300529"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102014","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymic epithelial tumors: From biology to treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102014"}}